Saqib Islam is Chief Executive Officer of Beeline Medicines, bringing more than 25 years of experience building and leading healthcare and life sciences companies to deliver life-changing medicines for patients. Mr. Islam previously served as Chief Executive Officer and a member of the Board of SpringWorks Therapeutics, where he built and led the company from its founding in 2017 through its evolution from a clinical-stage startup into a fully integrated, global, publicly traded commercial organization. Under his leadership, SpringWorks built a differentiated pipeline and commercial platform, and brought two novel, best-in-class therapies through global regulatory approvals and launches, with these medicines now serving patients living with devastating rare diseases around the world. His tenure at SpringWorks culminated in the company’s $3.9 billion acquisition by Merck KGaA, Darmstadt, Germany in 2025.
Prior to SpringWorks Therapeutics, Mr. Islam held executive leadership roles at Moderna Therapeutics and Alexion Pharmaceuticals, driving strategic growth and expanding global operations. Previously, Mr. Islam served in senior leadership positions in the global investment banking divisions of Morgan Stanley and Credit Suisse Securities. He currently serves on the Boards of Beeline Medicines and ARS Pharmaceuticals.
He received his J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar, and bachelor’s degree from McGill University, graduating as a Faculty and University Scholar.
